2023 journal article

Caveolin-1-derived peptide attenuates cigarette smoke-induced airway and alveolar epithelial injury.

American Journal of Physiology. Lung Cellular and Molecular Physiology.

By: D. Das *, B. Puthusseri *, V. Gopu *, V. Krishnan *, A. Bhagavath*, S. Bolla*, Y. Saini* , G. Criner* ...

TL;DR: Treatment of patients with COPD or mice with CS-LI with a seven amino acid caveolin-1 scaffolding domain peptide (CSP7) reduced mucus hypersecretion in AECs and improved AT2 cell viability and significantly improved lung function. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (OpenAlex)
Source: ORCID
Added: October 15, 2023

Chronic cigarette smoke (CS) exposure remains a major risk factor for the pathogenesis of COPD, a debilitating disease with no effective treatment. Increased caveolin-1 mediated induction of p53 and downstream plasminogen activator inhibitor-1 (PAI-1) expression contributes to CS-induced airway mucus hypersecretion and alveolar wall damage. This is reversed by caveolin-1 scaffolding domain peptide (CSP7) in preclinical models, suggesting the therapeutic potential of CSP7 for treating CS-induced lung injury (CS-LI) and COPD.